Comparison of next generation sequencing, SNaPshot assay and real-time polymerase chain reaction for lung adenocarcinoma EGFR mutation assessment

[1]  A. Warth,et al.  3001 Prevalence and clinical association of gene mutations through Multiplex Mutation Testing in patients with NSCLC: Results from the ETOP Lungscape Project , 2015 .

[2]  J. Vredenburgh,et al.  Targeting HER2 in the treatment of non-small cell lung cancer. , 2015, Lung cancer.

[3]  P. Petronini,et al.  Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer. , 2014, Biochemical pharmacology.

[4]  Baolan Li,et al.  Favorable response to icotinib in a lung cancer patient with a special mutation at exon 19 of epidermal growth factor receptor , 2014, Thoracic cancer.

[5]  C. Amos,et al.  Routine use of the Ion Torrent AmpliSeq™ Cancer Hotspot Panel for identification of clinically actionable somatic mutations , 2014, Clinical chemistry and laboratory medicine.

[6]  Geoffrey R. Oxnard,et al.  Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer , 2013, Science Translational Medicine.

[7]  P. Souquet,et al.  Routine EGFR Molecular Analysis in Non-Small-Cell Lung Cancer Patients is Feasible: Exons 18–21 Sequencing Results of 753 Patients and Subsequent Clinical Outcomes , 2013, Lung.

[8]  G. Giaccone,et al.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. , 2013, Archives of pathology & laboratory medicine.

[9]  R. Rosell,et al.  BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors. , 2013, Translational lung cancer research.

[10]  J. Duyster,et al.  Activating germline R776H mutation in the epidermal growth factor receptor associated with lung cancer with squamous differentiation. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Ashish Choudhary,et al.  Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens. , 2013, The Journal of molecular diagnostics : JMD.

[12]  Suzanne E Dahlberg,et al.  Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  Marc Ladanyi,et al.  EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics , 2013, Molecular Cancer Therapeutics.

[14]  Ying-jian Chen,et al.  Direct serum and tissue assay for EGFR mutation in non-small cell lung cancer by high-resolution melting analysis. , 2012, Oncology reports.

[15]  P. Laurent-Puig,et al.  Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples. , 2012, Experimental and molecular pathology.

[16]  P. Delvenne,et al.  The human epidermal growth factor receptor (EGFR) gene in European patients with advanced colorectal cancer harbors infrequent mutations in its tyrosine kinase domain , 2011, BMC Medical Genetics.

[17]  Primitiva Menéndez,et al.  Germ-line mutations in epidermal growth factor receptor (EGFR) are rare but may contribute to oncogenesis: A novel germ-line mutation in EGFR detected in a patient with lung adenocarcinoma , 2011, BMC Cancer.

[18]  A. V. D. van den Brule,et al.  SNaPshot and StripAssay as valuable alternatives to direct sequencing for KRAS mutation detection in colon cancer routine diagnostics. , 2011, The Journal of molecular diagnostics : JMD.

[19]  P. Jänne,et al.  Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors , 2011, Clinical Cancer Research.

[20]  P. Jänne,et al.  The biology and treatment of EML4-ALK non-small cell lung cancer. , 2010, European journal of cancer.

[21]  T. Chou,et al.  Pulmonary adenocarcinoma with microcystic histology and intratumoral heterogeneity of EGFR gene polymorphism , 2010, Histopathology.

[22]  David N Louis,et al.  Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine , 2010, EMBO molecular medicine.

[23]  Andigoni Malousi,et al.  Targeted KRAS Mutation Assessment on Patient Tumor Histologic Material in Real Time Diagnostics , 2009, PloS one.

[24]  A. Gazdar,et al.  Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors , 2009, Oncogene.

[25]  H. Koong,et al.  Using Whole Genome Amplification (WGA) of Low-Volume Biopsies to Assess the Prognostic Role of EGFR, KRAS, p53, and CMET Mutations in Advanced-Stage Non-small Cell Lung Cancer (NSCLC) , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[26]  H. Sasaki,et al.  EGFR polymorphism of the kinase domain in Japanese lung cancer. , 2008, The Journal of surgical research.

[27]  E. Stathopoulos,et al.  ‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer , 2007, British Journal of Cancer.

[28]  Daniel A. Haber,et al.  Epidermal growth factor receptor mutations in lung cancer , 2007, Nature Reviews Cancer.

[29]  L. Layfield,et al.  Detection of EGFR- and HER2-activating mutations in squamous cell carcinoma involving the head and neck , 2006, Modern Pathology.

[30]  T. Shibata,et al.  Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  M. Ladanyi,et al.  Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. , 2005, The Journal of molecular diagnostics : JMD.

[32]  T. Lynch.  The evolving story of the epidermal growth factor receptor as a target for non-small-cell lung cancer. , 2004, Clinical advances in hematology & oncology : H&O.

[33]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[34]  A. Iafrate,et al.  A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. , 2011, The Journal of molecular diagnostics : JMD.

[35]  T. Taguchi,et al.  Involvement of EGFR in the response of squamous cell carcinoma of the head and neck cell lines to gefitinib. , 2008, Oncology reports.